Literature DB >> 14646028

Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients.

Ming Ji1, Chengjie Xiong, Michael Grundman.   

Abstract

In this paper, we present a statistical hypothesis test for detecting a change point over the course of cognitive decline among Alzheimer's disease patients. The model under the null hypothesis assumes a constant rate of cognitive decline over time and the model under the alternative hypothesis is a general bilinear model with an unknown change point. When the change point is unknown, however, the null distribution of the test statistics is not analytically tractable and has to be simulated by parametric bootstrap. When the alternative hypothesis that a change point exists is accepted, we propose an estimate of its location based on the Akaike's Information Criterion. We applied our method to a data set from the Neuropsychological Database Initiative by implementing our hypothesis testing method to analyze Mini Mental Status Exam scores based on a random-slope and random-intercept model with a bilinear fixed effect. Our result shows that despite large amount of missing data, accelerated decline did occur for MMSE among AD patients. Our finding supports the clinical belief of the existence of a change point during cognitive decline among AD patients and suggests the use of change point models for the longitudinal modeling of cognitive decline in AD research.

Entities:  

Mesh:

Year:  2003        PMID: 14646028     DOI: 10.3233/jad-2003-5504

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  When does cognitive decline begin? A systematic review of change point studies on accelerated decline in cognitive and neurological outcomes preceding mild cognitive impairment, dementia, and death.

Authors:  Justin E Karr; Raquel B Graham; Scott M Hofer; Graciela Muniz-Terrera
Journal:  Psychol Aging       Date:  2018-03

2.  Cognitive Trajectory Changes Over 20 Years Before Dementia Diagnosis: A Large Cohort Study.

Authors:  Ge Li; Eric B Larson; Jane B Shofer; Paul K Crane; Laura E Gibbons; Wayne McCormick; James D Bowen; Mary Lou Thompson
Journal:  J Am Geriatr Soc       Date:  2017-09-21       Impact factor: 5.562

3.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Authors:  Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

4.  Estimating the temporal evolution of Alzheimer's disease pathology with autopsy data.

Authors:  Donald R Royall; Raymond F Palmer
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  A Bayesian hierarchical change point model with parameter constraints.

Authors:  Hong Li; Andreana Benitez; Brian Neelon
Journal:  Stat Methods Med Res       Date:  2020-09-13       Impact factor: 3.021

6.  Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.

Authors:  Patrick D Roberts; Athan Spiros; Hugo Geerts
Journal:  Alzheimers Res Ther       Date:  2012-11-26       Impact factor: 6.982

7.  Sample size and classification error for Bayesian change-point models with unlabelled sub-groups and incomplete follow-up.

Authors:  Simon R White; Graciela Muniz-Terrera; Fiona E Matthews
Journal:  Stat Methods Med Res       Date:  2016-08-08       Impact factor: 3.021

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.